EMA To Address Scientific Advances In Guidance For Flu Vaccine Innovators
Executive Summary
There is a sense of urgency around the need to include mRNA platforms and other scientific advances in the EU guideline on non-clinical and clinical requirements for influenza vaccine development, says the European Medicines Agency.
You may also be interested in...
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said.
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.
Drug Candidates For NASH & Epilepsy Disorder Secure EMA PRIME Designations
The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.